Related Experiment Video
Updated: Apr 20, 2026
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
Published on: August 29, 2017
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
Tianlei Ying1, Haoyang Li1, Lu Lu1
1Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China.
Abstract:
The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.
Insights
Recent advances in neutralizing monoclonal antibodies (mAbs) offer potential treatments for Middle East respiratory syndrome coronavirus (MERS-CoV) infections. This summary highlights mAb identification, mechanisms, and therapeutic potential against MERS-CoV.
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- The Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak presents a significant global public health challenge.
- Effective therapeutic strategies are crucial for managing MERS-CoV infections.
Purpose of the Study:
- To review recent advancements in the identification of human neutralizing monoclonal antibodies (mAbs) targeting MERS-CoV.
- To elucidate the mechanisms of action employed by these MERS-CoV neutralizing mAbs.
- To assess the therapeutic potential of these mAbs for treating MERS-CoV infections.
Main Methods:
- Literature review of studies identifying and characterizing human neutralizing monoclonal antibodies against MERS-CoV.
- Analysis of reported mechanisms of action for MERS-CoV specific mAbs.
- Evaluation of preclinical and clinical data on the efficacy of mAbs in MERS-CoV models.
Main Results:
- Several human neutralizing monoclonal antibodies (mAbs) against MERS-CoV have been successfully identified.
- These mAbs target key MERS-CoV structural proteins, inhibiting viral entry and replication.
- Demonstrated efficacy in preclinical models suggests therapeutic promise.
Conclusions:
- Human neutralizing mAbs represent a promising therapeutic avenue for MERS-CoV infections.
- Further research and clinical development are warranted to translate these findings into effective treatments.
- Monoclonal antibody therapies could play a vital role in future MERS-CoV outbreak preparedness.
